drugset

drugset / Trial / NCT04420689

Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery

NCT04420689 ↗

Phase 1/2 Completed 27 enrolled Alume Biosciences, Inc.

Non-randomizedSequentialOpen-labelPrevention

Summary

Bevonescein to Highlight Nerves in Patients Undergoing Head \& Neck Surgery

Timeline

Start: 2020-06-18
Primary completion: 2021-06-25
Completion: 2022-02-15

Publications

Lee YJ, Orosco RK, Bouvet M, Richmon JD, Berman BJ, Crawford KL, Hom M, Nguyen QT, Rosenthal EL. Intraoperative nerve-specific fluorescence visualization in head and neck surgery: a Phase 1 trial. Nat Commun. 2025 Jul 2;16(1):6060. doi: 10.1038/s41467-025-60737-x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevonescein	Peptide	500 mg	Intravenous

Indications